{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:20Z","timestamp":1790769320656,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"DOI":"10.1007\/s40263-026-01339-z","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:33:39Z","timestamp":1790760819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eculizumab and Ravulizumab During Pregnancy in Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis: Balancing Maternal Disease Control and Fetal Safety"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0116-9953","authenticated-orcid":false,"given":"Eva","family":"Dhupia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-5090","authenticated-orcid":false,"given":"Jennifer A.","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-1146","authenticated-orcid":false,"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"12","key":"1339_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1339_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13608-w","volume":"273","author":"ER Koc","year":"2026","unstructured":"Koc ER, Yetkin MF, Saridas F, Turan OF, Sevim S, Terzi M, et al. Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder. J Neurol. 2026;273(1):67.","journal-title":"J Neurol"},{"issue":"1","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14\u201324.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de Seze J, Levy M, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"issue":"7","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"1339_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/acn3.51683","volume":"9","author":"Q Du","year":"2022","unstructured":"Du Q, Shi Z, Chen H, Zhang Y, Qiu Y, Lang Y, et al. Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks. Ann Clin Transl Neurol. 2022;9(12):1918\u201325.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1339_CR7","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.18295\/squmj.2017.17.03.002","volume":"17","author":"A Hassan","year":"2017","unstructured":"Hassan A, Yasawy ZM. Myasthaenia gravis: clinical management issues before, during and after pregnancy. Sultan Qaboos Univ Med J. 2017;17(3):e259\u201367.","journal-title":"Sultan Qaboos Univ Med J"},{"key":"1339_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-026-13724-1","author":"L Miegel","year":"2026","unstructured":"Miegel L, Hickstein J, Reibelt A, Heesen C, Schubert C. Myasthenia gravis and pregnancy: a systematic review and meta-analysis. J Neurol. 2026. https:\/\/doi.org\/10.1007\/s00415-026-13724-1.","journal-title":"J Neurol"},{"issue":"11","key":"1339_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006338","volume":"96","author":"A Gustavsen","year":"2017","unstructured":"Gustavsen A, Skattum L, Bergseth G, Lorentzen B, Floisand Y, Bosnes V, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report. Med (Baltim). 2017;96(11):e6338.","journal-title":"Med (Baltim)"},{"issue":"40","key":"1339_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012584","volume":"97","author":"P Rovere-Querini","year":"2018","unstructured":"Rovere-Querini P, Canti V, Erra R, Bianchi E, Slaviero G, D\u2019Angelo A, et al. Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report. Med (Baltim). 2018;97(40):e12584.","journal-title":"Med (Baltim)"},{"issue":"5","key":"1339_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ajh.70268","volume":"101","author":"A Roth","year":"2026","unstructured":"Roth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, et al. Real-world effectiveness and safety of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: evidence from the International PNH Registry. Am J Hematol. 2026;101(5):939\u201348.","journal-title":"Am J Hematol"},{"issue":"15","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76(15):1310\u20135.","journal-title":"Neurology"},{"key":"1339_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696387","volume":"12","author":"P Singh","year":"2021","unstructured":"Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab pharmacokinetics and pharmacodynamics in patients with neuromyelitis optica spectrum disorder. Front Neurol. 2021;12:696387.","journal-title":"Front Neurol"},{"key":"1339_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1332890","volume":"15","author":"S Ortiz","year":"2024","unstructured":"Ortiz S, Pittock SJ, Berthele A, Levy M, Nakashima I, Oreja-Guevara C, et al. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Front Neurol. 2024;15:1332890.","journal-title":"Front Neurol"},{"issue":"5","key":"1339_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2022","unstructured":"Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele A, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin Nephrol. 2022;97(5):261\u201372.","journal-title":"Clin Nephrol"},{"issue":"3","key":"1339_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14712598.2023.2185131","volume":"23","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther. 2023;23(3):235\u201341.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1339_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ajg.2008.71","volume":"104","author":"SV Kane","year":"2009","unstructured":"Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104(1):228\u201333.","journal-title":"Am J Gastroenterol"},{"key":"1339_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/985646","author":"P Palmeira","year":"2012","unstructured":"Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012. https:\/\/doi.org\/10.1155\/2012\/985646.","journal-title":"Clin Dev Immunol"},{"issue":"11","key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1182\/bloodadvances.2025019253","volume":"10","author":"B Hochsmann","year":"2026","unstructured":"Hochsmann B, Gerber GF, Leopold W, Patel BJ, Gavriilaki E, Hefter A, et al. Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy. Blood Adv. 2026;10(9):3067\u201374.","journal-title":"Blood Adv"},{"issue":"2","key":"1339_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2025-001286","volume":"7","author":"A Jacob","year":"2025","unstructured":"Jacob A, Mahmoud A, Eldweik L, Mubashir A. Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report. BMJ Neurol Open. 2025;7(2):e001286.","journal-title":"BMJ Neurol Open"},{"issue":"3","key":"1339_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/cen3.12784","volume":"15","author":"T Fujimoto","year":"2024","unstructured":"Fujimoto T, Maeda Y. Eculizumab use throughout pregnancy in two patients with aquaporin-4-positive neuromyelitis optica spectrum disorder. Clin Exp Neuroimmunol. 2024;15(3):126\u20139.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"1","key":"1339_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/cen3.12807","volume":"16","author":"I Kister","year":"2025","unstructured":"Kister I, Wilson A. Response to: eculizumab use throughout pregnancy in two patients with aquaporin-4-positive neuromyelitis optica spectrum disorder. Clin Exp Neuroimmunol. 2025;16(1):4\u20135.","journal-title":"Clin Exp Neuroimmunol"},{"issue":"5","key":"1339_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/13524585241283648","volume":"31","author":"G Tommaso","year":"2025","unstructured":"Tommaso G, Damiano P, Pietro I. Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive NMOSD: a case report. Mult Scler. 2025;31(5):615\u20137.","journal-title":"Mult Scler"},{"key":"1339_CR25","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000001020","author":"A Java","year":"2026","unstructured":"Java A, Subramanian A, Nester C. Practical considerations for infection prevention with the clinical use of complement inhibitors. Clin J Am Soc Nephrol. 2026. https:\/\/doi.org\/10.2215\/CJN.0000001020.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1339_CR26","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2025-5-7","author":"B Karaman","year":"2025","unstructured":"Karaman B, Tuncel R, Ekmekci O, Adatepe NU, Yuceyar N. Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report. Drugs Context. 2025. https:\/\/doi.org\/10.7573\/dic.2025-5-7.","journal-title":"Drugs Context"},{"issue":"1","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000543216","volume":"17","author":"N Khalil","year":"2025","unstructured":"Khalil N, Guerra Hernandez C, Farias J, Murray K, Suresh N, Gooch C, et al. Safety and effectiveness of eculizumab throughout three pregnancies in a patient with refractory generalized myasthenia gravis: a case report. Case Rep Neurol. 2025;17(1):25\u201330.","journal-title":"Case Rep Neurol"},{"issue":"5","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1017\/cjn.2022.278","volume":"50","author":"X Li","year":"2023","unstructured":"Li X, Mehrabyan A. Managing myasthenia gravis with eculizumab monotherapy through pregnancy. Can J Neurol Sci. 2023;50(5):803\u20135.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"1339_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000511957","volume":"13","author":"T Vu","year":"2021","unstructured":"Vu T, Harvey B, Suresh N, Farias J, Gooch C. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol. 2021;13(1):65\u201372.","journal-title":"Case Rep Neurol"},{"key":"1339_CR30","doi-asserted-by":"crossref","unstructured":"Subramanian AK, Java A, Gupta SK, Gupta S, Bomback AS. Strategies to mitigate infection risk in patients receiving complement inhibitor therapy. Clin Infect Dis. 2026.","DOI":"10.1093\/cid\/ciag081"},{"issue":"4","key":"1339_CR31","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00277-025-06353-7","volume":"104","author":"JE Manning","year":"2025","unstructured":"Manning JE, Ciantar E, Griffin M, Kelly RJ. Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis. Ann Hematol. 2025;104(4):2517\u201325.","journal-title":"Ann Hematol"},{"issue":"2","key":"1339_CR32","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2017.7053","volume":"9","author":"K Zhang","year":"2017","unstructured":"Zhang K, Lu Y, Harley KT, Tran MH. Atypical hemolytic uremic syndrome: a brief review. Hematol Rep. 2017;9(2):7053.","journal-title":"Hematol Rep"},{"issue":"5","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.kint.2023.12.021","volume":"105","author":"M Che","year":"2024","unstructured":"Che M, Moran SM, Smith RJ, Ren KYM, Smith GN, Shamseddin MK, et al. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy. Kidney Int. 2024;105(5):960\u201370.","journal-title":"Kidney Int"},{"issue":"3","key":"1339_CR34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1681\/ASN.2016090995","volume":"29","author":"M Gaggl","year":"2018","unstructured":"Gaggl M, Aigner C, Csuka D, Szilagyi A, Prohaszka Z, Kain R, et al. Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29(3):1020\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1339_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3324\/haematol.2010.037531","volume":"96","author":"S de Guibert","year":"2011","unstructured":"de Guibert S, Peffault de Latour R, Varoqueaux N, Labussiere H, Rio B, Jaulmes D, et al. Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience. Haematologica. 2011;96(9):1276\u201383.","journal-title":"Haematologica"},{"key":"1339_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.544434","volume":"11","author":"R D'Souza","year":"2020","unstructured":"D\u2019Souza R, Wuebbolt D, Andrejevic K, Ashraf R, Nguyen V, Zaffar N, et al. Pregnancy and neuromyelitis optica spectrum disorder - reciprocal effects and practical recommendations: a systematic review. Front Neurol. 2020;11:544434.","journal-title":"Front Neurol"},{"issue":"2","key":"1339_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Socie","year":"2019","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297\u2013310.","journal-title":"Br J Haematol"},{"issue":"6","key":"1339_CR38","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/ejh.13946","volume":"110","author":"CCM Schaap","year":"2023","unstructured":"Schaap CCM, Heubel-Moenen F, Nur E, Bartels M, van der Heijden OWH, de Jonge E, et al. Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: evaluation of treatment indications and outcomes. Eur J Haematol. 2023;110(6):648\u201358.","journal-title":"Eur J Haematol"},{"key":"1339_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.543372","volume":"7","author":"F Alashkar","year":"2020","unstructured":"Alashkar F, Saner FH, Vance C, Schmucker U, Herich-Terhurne D, Duhrsen U, et al. Pregnancy in classical paroxysmal nocturnal hemoglobinuria and aplastic anemia-paroxysmal nocturnal hemoglobinuria: a high-risk constellation. Front Med (Lausanne). 2020;7:543372.","journal-title":"Front Med (Lausanne)."},{"issue":"5","key":"1339_CR40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.fertnstert.2023.08.954","volume":"120","author":"HG Genovese","year":"2023","unstructured":"Genovese HG, McQueen DB. The prevalence of sporadic and recurrent pregnancy loss. Fertil Steril. 2023;120(5):934\u20136.","journal-title":"Fertil Steril"},{"issue":"1","key":"1339_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1753495X211019899","volume":"15","author":"JE Manning","year":"2022","unstructured":"Manning JE, Anderson RM, Hill A, Zeidan D, Ciantar E. Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Obstet Med. 2022;15(1):45\u20139.","journal-title":"Obstet Med"},{"issue":"6","key":"1339_CR42","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","volume":"103","author":"N Miyasaka","year":"2016","unstructured":"Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol. 2016;103(6):703\u201312.","journal-title":"Int J Hematol"},{"issue":"22","key":"1339_CR43","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1182\/blood.V128.22.2397.2397","volume":"128","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova M, Kulagin A, Shmakov R, Kirsanova T, Mikhailova E, Klimova O, et al. The pregnancy course and outcomes during targeted therapy of paroxysmal nocturnal hemoglobinuria. Blood. 2016;128(22):2397.","journal-title":"Blood"},{"issue":"1","key":"1339_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000518171","volume":"146","author":"E Rondeau","year":"2022","unstructured":"Rondeau E, Ardissino G, Caby-Tosi MP, Al-Dakkak I, Fakhouri F, Miller B, et al. Pregnancy in women with atypical hemolytic uremic syndrome. Nephron. 2022;146(1):1\u201310.","journal-title":"Nephron"},{"issue":"5","key":"1339_CR45","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40620-021-01025-x","volume":"34","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol. 2021;34(5):1581\u201390.","journal-title":"J Nephrol"},{"key":"1339_CR46","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1182\/blood-2021-145076","volume":"138","author":"F Amisha","year":"2021","unstructured":"Amisha F, Konda M, Malik P, Roy AM, Sasapu A. Clinical-laboratory- genetic profile and outcomes of patients with atypical hemolytic uremic syndrome and restrictive use of eculizumab: a single center experience and a brief review. Blood. 2021;138:3159.","journal-title":"Blood"},{"issue":"2","key":"1339_CR47","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","volume":"93","author":"A Huerta","year":"2018","unstructured":"Huerta A, Arjona E, Portoles J, Lopez-Sanchez P, Rabasco C, Espinosa M, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int. 2018;93(2):450\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"1339_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","volume":"135","author":"M Gupta","year":"2020","unstructured":"Gupta M, Govindappagari S, Burwick RM. Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review. Obstet Gynecol. 2020;135(1):46\u201358.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"1339_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041403","volume":"104","author":"P Meena","year":"2025","unstructured":"Meena P, Gala R, Das RR, Bhargava V, Saivani Y, Panda S, et al. Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Med (Baltim). 2025;104(5):e41403.","journal-title":"Med (Baltim)"},{"issue":"4","key":"1339_CR50","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.kint.2019.01.012","volume":"95","author":"C Duineveld","year":"2019","unstructured":"Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar N, Wetzels JFM. Placental passage of eculizumab and complement blockade in a newborn. Kidney Int. 2019;95(4):996.","journal-title":"Kidney Int"},{"issue":"1","key":"1339_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1469-9","volume":"20","author":"S Nagarajah","year":"2019","unstructured":"Nagarajah S, Tepel M, Nielsen C, Assing K, Palarasah Y, Andersen LLT, et al. Reduced membrane attack complex formation in umbilical cord blood during eculizumab treatment of the mother: a case report. BMC Nephrol. 2019;20(1):307.","journal-title":"BMC Nephrol"},{"issue":"4","key":"1339_CR52","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","volume":"220","author":"RF Hallstensen","year":"2015","unstructured":"Hallstensen RF, Bergseth G, Foss S, Jaeger S, Gedde-Dahl T, Holt J, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220(4):452\u20139.","journal-title":"Immunobiology"},{"issue":"4","key":"1339_CR53","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/sji.12154","volume":"79","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Ceccon ME, Rutz R, Fertig A, Kirschfink M. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79(4):276\u201381.","journal-title":"Scand J Immunol"},{"key":"1339_CR54","unstructured":"ULTOMIRIS\u00ae Ravulizumab for injection. Product Monograph. Available from: 2023 Oct 30 [cited 2026 Mar 24]."},{"issue":"Supplement 1","key":"1339_CR55","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1182\/blood-2025-4458","volume":"146","author":"H Sherrard","year":"2025","unstructured":"Sherrard H, Infante C, Mujeebuddin A, Williams C. Safety of ravulizumab use in pregnancy: insights from a global pharmacovigilance analysis. Blood. 2025;146(Supplement 1):4458.","journal-title":"Blood"},{"issue":"3","key":"1339_CR56","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1474-4422(25)00479-X","volume":"25","author":"DL Rotstein","year":"2026","unstructured":"Rotstein DL, Alroughani R, Arrambide G, Contentti EC, Chomba M, Fujihara K, et al. Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD. Lancet Neurol. 2026;25(3):308\u201324.","journal-title":"Lancet Neurol"},{"key":"1339_CR57","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2024-208645","volume":"144","author":"D Knight","year":"2024","unstructured":"Knight D, Patel BJ. Ravulizumab treatment during pregnancy: a case report. Blood. 2024;144:5688\u20139.","journal-title":"Blood"},{"issue":"2","key":"1339_CR58","volume":"16","author":"Y Miyazaki","year":"2024","unstructured":"Miyazaki Y, Fukuda M, Hirayu N, Nabeta M, Takasu O. Pregnancy-associated atypical hemolytic uremic syndrome successfully treated with ravulizumab: a case report. Cureus. 2024;16(2):e54207.","journal-title":"Cureus"},{"key":"1339_CR59","unstructured":"Centers for Disease Control and Prevention. Clinical guidance for managing meningococcal disease risk in patients receiving complement inhibitor therapy. November 26, 2024 [cited]; Available from: https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical-guidance\/complement-inhibitor.html."},{"issue":"2","key":"1339_CR60","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1097\/MPH.0000000000002075","volume":"44","author":"SH Graciaa","year":"2022","unstructured":"Graciaa SH, Graciaa DS, Yildirim I, Chonat S. Risk of disseminated gonococcal infections with terminal complement blockade. J Pediatr Hematol Oncol. 2022;44(2):e493\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"1339_CR61","doi-asserted-by":"publisher","first-page":"e2225438","DOI":"10.1001\/jamanetworkopen.2022.25438","volume":"5","author":"L Wang","year":"2022","unstructured":"Wang L, Su M, Zhou Z, Zhou L, ZhangBao J, Tan H, et al. Analysis of pregnancy-related attacks in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(8):e2225438.","journal-title":"JAMA Netw Open"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01339-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01339-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01339-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:01:50Z","timestamp":1790766110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01339-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":61,"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01339-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ED reports no conflicts of interest. JAM reports grant funding from the University of Alberta Department of Medicine, consulting fees from Novartis, educational honoraria from the American Academy of Neurology, and participation in an advisory board for Horizon. SJP has received personal compensation for consulting for Roche\/Genentech, Sage Therapeutics, Astellas, and Arialis, and for serving on scientific advisory boards or data safety monitoring boards for F. Hoffmann-La Roche AG, Genentech, and UCB. His institution has received compensation for consulting for Astellas, Alexion\/AstraZeneca Rare Disease, and Horizon\/Amgen, and research support from Alexion\/AstraZeneca Rare Disease, Horizon\/Amgen, and F. Hoffmann-La Roche AG\/Genentech. All compensation is paid to Mayo Clinic. He holds issued patents related to neuromyelitis optica (Patent# 8,889,102 and 9,891,219B2) and receives royalties. NN serves on advisory boards and as a consultant for Novartis, Roche, EMD Serono, and Alexion, and has received research funding from MS Canada.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ED and NN drafted the manuscript. JAM, and SJP provided critical input and revised the manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":2,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI tools were used for this review.","order":8,"name":"Ethics","label":"AI Use","group":{"name":"EthicsHeading","label":"Declarations"}}]}}